Grunebaum Foundation Newsletters

If you would like to receive the Karin Grunebaum Cancer Research Foundation Newsletter please contact

The Board of Trustees sincerely thank Lorraine O'Grady for donating her time and energy to designing every edition of the Karin Grunebaum Cancer Research Foundation Newsletter since 2004.

Volume 20 - November 2023 view.pdf

KGCRF Nobel Prize winner for Covid vaccine; molecular devices that promote carginogenesis; mediation of tumor control and rejection; muscle invasive bladder cancer; ER+ breast cancer modeling; catalyst cancer awards.

Volume 19 - November 2022 view.pdf

Thanks to members of the Karin Grunebaum family for service to the Foundation; insights into current and future medical accomplishments by Fellows; Boston University School of Medicine Distinguished Alumni Award to Fellow Drew Weissman; detection of lung cancer in African American women; understanding the molecular mechanisms of tumor heterogeneity and clonal evolution of genitourinary tumors; activating the immune system with immunotherapy to eliminate refractory breast tumors; defining the roles of antibodies produced by cancerous immune cells in multiple myeloma and related hematological conditions; dissecting the fundemental mechanisms by which PD-1 is regulated in dysfunctional  tumor-infiltrating T cells; whole-genome doubling confers unique genetic vulnerabilites on tumor cells; Karin Grunebaum Foundation's cancer poster competition at Harvard Medical School; Karin Grunebaum Foundation's cancer biology program/professional development curriculum at Harvard Medical School.

Volume 18 - December 2021 view.pdf

Foundation’s role in development of Covid vaccine; KGCRF Professor Palmer develops breast cancer prediction tool; KGCRF Fellow Weissman named BUSM Distinguished Alumni; synopsis of KGCRF poster competition winners’ posters; roles of antibody stability in plasma cell cancers; epigenetic regulation and functional consequences of chronic PD-1 expression in anti-tumor immunity; developing chemical compounds that overcome the differential block in colorectal cancer.

Volume 17 - December 2020 view.pdf

Continued operations and donations during Covid pandemic; established HMS Professional Development Program; established Twitter presence;  TBK1 as a target to reprogram the tumor immune microenvironment; NEURL4 as a tumor suppressor in non-small-cell-lung cancer (NSCLC); Karin Grunebaum poster winners and poster synopsis; using endogenous cell lines for genetic and drug screens; identifying epigenetic/transcriptional vulnerabilities mediated by Corin associated with cell plasticity and resensatization in MAPKE-resistant melanoma.

Volume 16 - December 2019 view.pdf

Julie Palmer, Sc.D., M.P.H., appointed as second Karin Grunebaum Professor in Cancer Research.  TBK1 as a novel target to reprogram tumor immune microenvironment. Correlation between mitochondrial dysfunction and mitochondrial DNA instability in the regulation of immune response and metabolic reprogramming during cellular stress in lung cancer. New imaging and therapeutic agents targeting hypoxia in solid tumors. Wound healing after transoral CO2 laser surgery for early glottic carcinoma. BUSM 2019 summer research project summaries. HMS third annual poster contest winners’ project abstracts.  

Volume 15 - November 2018 view.pdf

Foundation's 60th (Diamond) Anniversary, with synopsis of accomplishments. Welcome new Trustee: Genevieve Boland, M.D., Ph.D. Molecular underpinnings of prostate cancer disparities. Geonomic atlas of pre-cancerous lung lesions. Tumor hypoxia. Developing a miRNA signature to differentiate metastatic head and neck cancer from lung squamous cell carcinoma. Impact of locoregional treatment on metastatic breast cancer.  How heterotrimeric G protein activators "rewire" signal transduction in cancer. Elucidating biosynthetic pathways and biological functions of small molecules to design, synthesize and utilize small molecules to probe and manipulate human bacteria in vivo. Winners of HMS 2018 cancer poster competition.

Volume 14 - October 2017 view.pdf

1st annual Karin Grunebaum cancer poster competition results at Harvard Medical School; 10 applicants for Fellowship at Harvard Medical School; By-laws amended to allow 6-year faculty members to extend Fellowship for a second year at Boston University School of Medicine; immune checkpoints in blood-based monitoring of melanoma; microbial imbalance in the human microbione; molecular mechanisms by which cells respond to external signals.

Volume 13 - October 2016 view.pdf

1st annual Karin Grunebaum cancer poster contest funded at HMS. Identify clinically-meaningful assays to detect melanoma markers in the blood, risk stratification tools for melanoma patients, identifying predictive signatures of response/non-response to systemic therapy. Elucidating the molecular mechanisms by which cells respond to external signals and how dysregulation of these mechanisms lead to cancer progression.  Epigenic regulation of growth-promoting and tumor suppressing genes in ovarian cancer. Reducing socioeconomic disparity in skull base tumor patients.

Volume 12 - October 2015 view.pdf

Identifying the tumor suppressor mechanism that limits proliferation of oncogenic tetraploid cells. Inhibiting ATR may be therapeutic approach to aggressive cancers. Letters from BU summer medical students. Fellow Neil Ganem, named first BUSM Searle Scholar. Fellow Rick Wison published in Cancer Cell journal. Meet new Trustee, Adam Lerner, M.D. 

Volume 11 - November 2014 view.pdf

Introduction of new Trustees; gratitude to departing Trustees; Cytokinesis Failure Triggers Hippo Tumor Suppresor Pathway Activation; Fellow Rachel Flynn, Ph. D awarded Peter Paul Professorship; Epigenetic Regulations and Melanoma; Mesenchymal Stem Cells (MSCs) and Desmond Tumorgenesis, Part 2.

Volume 10 - November 2013 view.pdf

Death of Trustee Merrill Feldman, MD; introduction of current Trustees; Targeting Vulnerabilities of MYC-related Cancers; Fellow Hui Feng, MD, Ph.D awarded Ralph Edwards Career Professorship; Role of GPS2 as a Tumor Suppressor and Regulator of the Balance between Pro-survival and Pro-apophic Responses; Mesenchymial Stem Cells (MSCs) and Desmoid Tumorigenesis (Part 1); HMS Cancer Biology Area of Concentration in Biological and Biomedical Sciences Graduate Program. 

Volume 9 - October 2012 view.pdf

Thank you for donations. Foundation's support of HMS Biological and Biomedical Science Graduate Program. Foundation's support of BUSM summer cancer Fellowships.  B-cell Chronic Lymphocytic Leukemia (B-CLL).  Anticoagulant effect on metastasis.

Volume 8 - October 2011 view.pdf

Foundation adds support to student cancer research programs at Harvard and BU medical schools.  Using cancer genomes to better understand esophagael and gastric adenocarcinomas.  Defining polarity cues that promote tumor suppression.  Cancer stem cells in solid tumors.  Metabolomics of colorectal cancer.  Synergistic type growth inhibitors in breast cancer cells using HDAC inhibitors and Capain inhibitor in combination.

Volume 7 - October 2010 view.pdf

Fellow Michael Roehrl, M.D., Ph. D. '10 wins Young Investigator Award from Human Proteome Organization. Karin Grunebaum's youngest grandchildren, Christopher Kelly and Shawna Wallach, join Board of Trustees. Identification of novel NF-kB pathway regulators in lymphomagenesis. Molecular and functional characteriization of cancer stem cells in pancreatic cancer. Transformative pathology and systems biology of cancer. 

Volume 6 - October 2009 view.pdf

Foundation increased funding during economic turmoil. Welcome new Trustees: Dean David Golan of Harvard Medical School and Dr. Frank Hsu (Karin Grunebaum Fellow 1986) of Genzyme Corporation. Dr. Iacobuzio-Donahue (Karin Grunebaum Fellow 1996) wins Ramzi Cotran research award from Academy of Pathology. Determining whether Fbw7 regulates KLF4 in a GSK-3 dependent manner. Determining whether elevated KLF4 expression plays a critical role in development of T-ALL after loss of the Fbw7 tumor suppressor. Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. SIRT 1 in prostate cancer development and progression.

Volume 5 - October 2008 view.pdf

50th Anniversary, BU and Harvard thank Foundation, Dean Michel new Trustee, New website honors former Newsletters, Activation of Senescence Program in Tumor Cells Suppresses Major DNA Repair Factor H2A.X., Sonic Hedgehog in Tumor Angionesis a Potential Target for Anti-angionenic Therapy in Pancreatic Cancer; Contibution of Tregs in Patients with Resectable Pancreatic Adenocarcinoma.  

Volume 4 - October 2007 view.pdf

Redirecting Foundation's focus to support faculty cancer researchers; CK2 Regulation Of Wnt Signaling in breast cancwer; Pancreatic Cancer Tumor Response to Sonic Hedgehog Pathway; Immune Escape Mechanisms in Pancreatic Adonocarcinoma Cells.

Volume 3 - October 2006 view.pdf

Newslettership program with the Massachusetts General Hospital; What’s "Fueling your" Leukemia?; Finding the Target: Identifying the Mechanism of Gefitinib Induced Acute Myeloid Leukemia Differentiation; A Novel Mouse Model for the Study of Chronic Graft-versus-Host Disease; Meet The Foundation’s New Trustees

Volume 2 - October 2005 view.pdf

Environmental Toxins and Breast Cancer; Prostate Specific Antigen doubling time; Microscopy: An Art of Science; Pretreatment of Splenic B lymphocytes with bacterial products induces and alternate signaling pathway.

Volume 1 - October 2004 view.pdf

Steven Wallach assumes leadership of KGCRF; HMS Karin Grunebaum Foundation Newslettership Report; The History of the Grunebaum Foundation at Boston University School of Medicine; THE TROPHIC EFFECTS OF GASTRIN ARE MEDIATED BY ATTENUATION OF PPARgð SUPPRESSION OF CELL GROWTH